Table 3

Results for CRP-positive and CRP-negative patients
CRP-positive patients CRP-negative patients
Baseline value Adjusted mean changes (95% CI) P-value Baseline value Adjusted mean changes (95% CI) P-value
<4 years ≥4 years <4 years ≥4 years
n = 30 n = 15 n = 26 n = 37
BASDAI 5.4 3.3 (2.7, 4.0) 2.4 (1.5, 3.3) 0.11 5.5 3 (2.3, 3.7) 1.3 (0.7, 1.9) 0.001
BASFI 4.2 2.4 (1.8, 3.0) 1.8 (0.9, 2.7) 0.23 4.5 2.4 (1.8, 3.1) 0.9 (0.4, 1.5) 0.001
BASMI 1.5 0.1 (−0.3, 0.4) 0.4 (−0.1, 0.9) 0.30 2.0 0.5 (0, 1) −0.3 (−0.6, 0.1) 0.01
ASDAS 3.6 1.9 (1.6, 2.2) 1.5 (1.1, 1.9) 0.07 2.8 1.3 (1, 1.6) 0.6 (0.3, 0.8) 0.001
CRP* 13.8 2.7 (2.2, 3.3) 2.1 (1.5, 3) 0.20 3.6 1.2 (1, 1.5) 1.2 (1, 1.4) 0.86
MRI SIJ 6.6 4.6 (3.6, 5.7) 3.5 (2, 4.9) 0.19 3.8 2.5 (1.8, 3.2) 2.5 (1.9, 3.1) 0.96

*Log-transformed CRP results were back-transformed; P-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.

Weiß et al.

Weiß et al. Arthritis Research & Therapy 2014 16:R35   doi:10.1186/ar4464

Open Data